7月3日，江西生物盘中上涨9.52%，报6.82港元，成交额189.37万港元。
消息面上，公司早间公告，旗下全资子公司赤峰博恩药业有限公司近期成功取得兽用破伤风抗毒素产品《兽药产品批准文号批件》，该产品主要用于预防及治疗动物破伤风感染。此前市场对公司人用TAT单一产品高度依赖（营收占比超96%）存在担忧，本次兽用产品获批有望改善产品结构单一的格局，打开兽用市场空间。公司6月30日以11.2港元发行价上市首日即破发，此后股价持续走低，本次利好消息释放后股价出现反弹。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.